Roche Diagnostics announced as sponsor of Hypo Awareness Week 2026
Hypo Awareness Week 2026 has been funded by Roche, which has had no input into the campaign's arrangements or content.
We anticipate that the campaign will receive further sponsorship from pharmaceutical companies and medical technology companies. Once confirmed it will be added to the relevant pages of the Hypo Awareness Week website and Hypo Awareness Week promotional materials, where appropriate.
Roche Diagnostics has been confirmed as an official sponsor of Hypo Awareness Week 2026, supporting the campaign’s mission to bring together healthcare professionals across the UK to raise awareness of hypoglycaemia and promote safer diabetes care.
Taking place from the 14 to 20 September 2026, Hypo Awareness Week aims to increase understanding of hypoglycaemia (hypo) – a condition that occurs when blood glucose levels fall too low. If not recognised and treated promptly, hypoglycaemia can lead to serious complications and in some cases become life-threatening.
Following the success of last year's campaign, which saw more than 700 healthcare sites take part, Hypo Awareness Week 2026 aims to build on this momentum by helping organisations strengthen their approach to hypo prevention, recognition and management.
“Hypo Awareness Week provides a valuable opportunity for healthcare professionals to come together, share learning and raise awareness of the impact hypoglycaemia can have on people living with diabetes,” said event manager Emily Mayhew.
Hypoglycaemia remains a significant concern for people living with diabetes and for those admitted to hospital, where it is associated with increased complications and poorer clinical outcomes.
To support local awareness activities, registered sites will receive free access to a range of printed and digital campaign resources designed to help educate both healthcare professionals and people living with diabetes.
This sponsorship follows Roche Diagnostics recent announcement that its Accu-Chek® SmartGuide continuous glucose monitoring (CGM) system is now reimbursable on the NHS, providing adults living with diabetes easier access to the technology. This decision makes it the first artificial intelligence (AI)-driven CGM in the UK capable of predicting nighttime hypoglycaemia.
Peter Hampson, Head of Medical Affairs at Roche Diagnostics UK & Ireland, said: “Research suggests that between two to five per cent of deaths in people under 40 living with type 1 diabetes are linked to nighttime hypoglycaemia, so for many people living with diabetes, the fear of blood sugar dropping overnight is a constant worry.
“Our technology helps reduce some of that uncertainty by predicting potential lows before they occur, giving people greater confidence and peace of mind in their day-to-day lives. Roche Diagnostics is incredibly proud to be helping people feel safer and more in control of their diabetes and to be supporting Hypo Awareness Week 2026."
Using AI, the system analyses glucose patterns to forecast levels over the next 30 minutes, two hours and throughout the night and prompts users to take action if their glucose is expected to drop below a safe range. A water-resistant sensor worn on the back of the upper arm sends readings to a smartphone app every five minutes, helping people stay informed and take action before low blood sugar becomes a problem.
Registration for Hypo Awareness Week 2026 is now open to healthcare settings across the UK. Registered sites can access a range of free campaign resources, although printed materials are available on a first-come, first-served basis.
To register please complete this form.
For more information about Hypo Awareness Week 2026 visit www.hypoawarenessweek.com
Hypo Awareness Week 2026 has been funded by Roche, which has had no input into the campaign's arrangements or content.
We anticipate that the campaign will receive further sponsorship from pharmaceutical companies and medical technology companies. Once confirmed it will be added to the relevant pages of the Hypo Awareness Week website and Hypo Awareness Week promotional materials, where appropriate.